NEW HAVEN, Conn., May 09, 2016 (GLOBE NEWSWIRE) -- Woodbridge International, a global mergers and acquisitions firm, is pleased to announce the acquisition of its client Immunostics, Inc. by Boditech Med, Inc.
Based in Ocean, New Jersey, Immunostics develops, manufactures and sells FDA-approved microbiological, serological and immunological diagnostic kits and reagents. The Company’s flagship products test for fecal occult blood as an indicator of the presence of colorectal cancer or other gastro-intestinal disorders. Immunostics holds several U.S. and international patents and trademarks, with many more pending.
Boditech Med markets its own brand of point-of-care diagnostic products to more than 70 countries. Headquartered in Seoul, South Korea, Boditech is a public company listed on the KOSDAQ. A world leader in in vitro diagnostics, Bodietch Med has a product portfolio of 33 diagnostic reagents.
In Immunostics, Boditech found a business partner with FDA-approved products, a strong distribution channel and 33 years of proven product quality.
”The pipeline of high quality, differentiated and cost-effective products that this new partnership brings will be of great benefit to our employees, as well as to our customers and suppliers, for many years to come," said Immunostics President Kenn Kupits.
Headquartered in New Haven, CT, Woodbridge International, a global M&A firm, was founded in 1993 and has 11 offices in the U.S. and 22 offices abroad.